1-3 of 3
Tobias Menne
Close
Sort by
Journal Articles

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Clinical Trials & Observations
Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew J. Davies, Dima El-Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah, Ying Ying Peng, Iman Qureshi, Juanah Addada, Rocio Figueroa Mora, Neil Phillips, Andrea Kuhnl, Elizabeth Davies, David Wrench, Pamela McKay, Indrani Karpha, Anna Cowley, Richard Karim, Sarah Challenor, Vikram Singh, Cathy Burton, Rebecca Auer, Chris Williams, Joel Cunningham, Angus Broom, Anita Arasaretnam, Claire Roddie, Tobias Menne, William Townsend
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2920–2926.
https://doi.org/10.1182/bloodadvances.2021005953
Published: 2022
Includes: Supplemental data
Journal Articles

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma

Clinical Trials & Observations
Andrea Kuhnl, Claire Roddie, Amy A. Kirkwood, Tobias Menne, Maria Cuadrado, Maria A. V. Marzolini, Wendy Osborne, Robin Sanderson, Maeve O’Reilly, William Townsend, Reuben Benjamin, Victoria Potter, Piers E. M. Patten, Deborah Yallop, Stefan Voo, George S. Petrides, Nicola Mulholland, Irfan Kayani
Journal: Blood Advances
Blood Adv (2022) 6 (1): 321–326.
https://doi.org/10.1182/bloodadvances.2021005807
Published: 2022
Journal Articles

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Sarah E. Fordham, Helen J. Blair, Claire J. Elstob, Ruth Plummer, Yvette Drew, Nicola J. Curtin, Olaf Heidenreich, Deepali Pal, David Jamieson, Catherine Park, John Pollard, Scott Fields, Paul Milne, Graham H. Jackson, Helen J. Marr, Tobias Menne, Gail L. Jones, James M. Allan
Journal: Blood Advances
Blood Adv (2018) 2 (10): 1157–1169.
https://doi.org/10.1182/bloodadvances.2017015214
Published: 2018
Includes: Supplemental data